All News

Ahead of the Sports Pharmacy Summit, Erin Dorval, PharmD, highlights the pharmacist’s role in optimizing athlete performance and recovery through safe medication use, careful supplement evaluation, and a holistic, risk-minimizing approach to care.

The first-in-class triple agonist met all primary and key secondary end points in the TRANSCEND-T2D-1 trial.

The National Association of Boards of Pharmacy (NABP) opens the door to the Occupational English Test (OET) as an alternative English exam for foreign pharmacy graduate certification.

This annual recognition was established by the Hematology/Oncology Pharmacy Association (HOPA) to honor the essential contributions of hematology/oncology pharmacists to the lives of people affected by cancer.

Circulating tumor DNA detected after neoadjuvant therapy may serve as a powerful biomarker for minimal residual disease and help predict breast cancer recurrence.

A new 20-year analysis reveals persistent inequities in influenza vaccination among a high-risk cardiovascular population.

Pharmacy supply chain disruptions directly shape the treatment that patients receive, making it vital that pharmacists understand the causes and consequences of delays.

Brandon Welch, PharmD, highlights the expanding role of sports pharmacists in medication safety, anti-doping, and personalized athlete care.

Pulse by NABP is revolutionizing drug supply chain oversight and patient safety.

AHA Epidemiology Sessions 2026 show that chronic kidney disease (CKD) proteinuria drops of 30% or more cut heart failure, major adverse cardiovascular events, and death, a key prevention signal.

As pharmacy technology consolidates under a few powerful platforms, independent pharmacies risk losing control of the data—and leverage—they generate every day.

Deucravacitinib offers a targeted, well-tolerated oral option for patients with psoriatic arthritis, with efficacy comparable to biologics and meaningful benefits in patient-reported outcomes.

The approval is supported by clinical data from the ATTAIN-1 and ATTAIN-2 trials.

The updated dosing schedule for nusinersen offers increased drug exposure and may further improve outcomes for patients with spinal muscular atrophy.

There was limited evidence supporting additional clinical benefits.

Jonathan Leung, PharmD, RPh, BCPS, discusses the ongoing underutilization of clozapine despite its efficacy, highlighting clinician concerns, lingering perceptions, and the key role pharmacists play in improving its use through education and monitoring.

Fluvoxamine significantly reduced fatigue in adults with long COVID, with a 99% probability of outperforming placebo.

At APhA 2026, Callan Bleick, PharmD, MSc, laid out a stark picture of antimicrobial resistance, vaccine-preventable disease resurgence, and updated treatment guidelines.

Explore OTC case studies focused on pain management.

NABP weighs OET and best-section scoring to ease FPGEE path while boosting pass rates and safeguarding patient care.

A FINEARTS-HF subgroup analysis shows patients with HFpEF and comorbid sleep apnea face a 43% higher adjusted cardiovascular risk.

Selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naive myelofibrosis, supporting its potential as a novel frontline combination strategy.

Martinez Sanchez describes early signs of Parkinson disease, how treatment adapts, and how ambulatory pharmacists fine-tune treatment, adherence, and hope amid new therapies.

Experts from NABP and the Arkansas State Board of Pharmacy explain how Pulse by NABP equips pharmacists and regulators with real-time drug supply chain verification tools.

Pharmacists' role in lipid management takes center stage with the 2026 dyslipidemia guideline update.

Clinical pharmacist specialists emphasized the pharmacist's role closing the gap between guideline recommendations and patient access to CGMs and automated insulin delivery.